Last €5.28 EUR
Change Today -0.081 / -1.51%
Volume 33.2K
As of 4:31 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

mdxhealth (MDXH) Snapshot

Open
€5.35
Previous Close
€5.36
Day High
€5.35
Day Low
€5.25
52 Week High
02/24/15 - €5.88
52 Week Low
07/17/14 - €3.07
Market Cap
198.7M
Average Volume 10 Days
347.1K
EPS TTM
€-0.30
Shares Outstanding
37.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MDXHEALTH (MDXH)

Related News

No related news articles were found.

mdxhealth (MDXH) Related Businessweek News

No Related Businessweek News Found

mdxhealth (MDXH) Details

MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic assays and services for cancer assessment, and the personalized treatment of patients. It offers clinical molecular diagnostics solutions that provide physicians with tests for the identification and treatment of their cancer patients; and pharmaco molecular diagnostics solutions for the development of companion diagnostics, biomarker discovery, and clinical trial testing. The company’s product pipeline consists of ConfirmMDx that serve as an aid for physicians to assess DNA methylation status associated with presence or absence of cancer; and InformMDx, which provide prognostic assessment to distinguish between aggressive and non-aggressive tumors. Its products also comprise PredictMDx that offer predictive information to indicate drugs or treatment regimens that are to be most effective for the individual patient; and ClinicalMDx assays that are designed to aid in the assessment of the presence or absence of cancer, or provide indications of cancer recurrence or aggressiveness in the areas of prostate, colorectal, and lung cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA on October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.

84 Employees
Last Reported Date: 04/30/14
Founded in 2003

mdxhealth (MDXH) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €470.7K
Compensation as of Fiscal Year 2013.

mdxhealth (MDXH) Key Developments

MDxHealth SA Announces Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

MDxHealth SA announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of €3,372,000 compared to €1,576,000 a year ago. LBITDA was €3,611,000 compared to €4,234,000 a year ago. Operating loss (LBIT) was €3,705,000 compared to €4,299,000 a year ago. Net loss was €3,019,000 compared to €4,387,000 a year ago. Basic earnings per share, basic were €0.08 against €0.13 a year ago. The increase revenues compared to the prior period was due to increased sales of ConfirmMDx and royalty and milestone payments from Exact Sciences. For the year, the company reported total revenues of €11,671,000 compared to €7,554,000 a year ago. LBITDA was €15,009,000 compared to €15,653,000 a year ago. Operating loss (LBIT) was €15,342,000 compared to €16,071,000 a year ago. Net loss was €15,256,000 compared to €16,175,000 a year ago. Basic earnings per share, basic were €0.40 against €0.47 a year ago. This loss is attributed to the continued investment in commercialization efforts in the U.S. and the delay in recognizing revenues from ConfirmMDx sales. For the fiscal year 2015, the company’s revenue expected to be between $16 million to $20 million.

MDxHealth SA to Report Fiscal Year 2014 Results on Feb 26, 2015

MDxHealth SA announced that they will report fiscal year 2014 results at 8:00 AM, Central European Standard Time on Feb 26, 2015

MDxHealth SA Grants Limited Worldwide License for its Patented Methylation Specific PCR Technology to oncgnostics GmbH in Jena

MDxHealth SA has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany. Under the agreement, MDxHealth grants oncgnostics a limited, non-transferable, non-exclusive, worldwide license for its patented methylation specific PCR (MSP) technology for diagnostic applications in cervical cancer. In return, MDxHealth will receive upfront and milestone payments, and royalties on net sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXH:BB €5.28 EUR -0.081

MDXH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Laboratories Inc $35.30 USD +0.36
Health Discovery Corp $0.02 USD +0.0026
Imperial Innovations Group PLC 457.50 GBp 0.00
Miraculins Inc C$0.18 CAD -0.015
Vermillion Inc $1.89 USD +0.03
View Industry Companies
 

Industry Analysis

MDXH

Industry Average

Valuation MDXH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.0x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MDXHEALTH, please visit www.mdxhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.